Founders Financial Alliance LLC Has $2.59 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Founders Financial Alliance LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,927 shares of the company’s stock after selling 597 shares during the period. Johnson & Johnson accounts for 0.7% of Founders Financial Alliance LLC’s investment portfolio, making the stock its 29th biggest holding. Founders Financial Alliance LLC’s holdings in Johnson & Johnson were worth $2,593,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of JNJ. IFS Advisors LLC increased its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the period. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth $32,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth about $35,000. Activest Wealth Management acquired a new position in shares of Johnson & Johnson during the third quarter valued at about $40,000. Finally, NewSquare Capital LLC lifted its stake in shares of Johnson & Johnson by 145.8% in the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock valued at $42,000 after buying an additional 172 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 0.5 %

Shares of JNJ opened at $167.57 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market cap of $403.45 billion, a price-to-earnings ratio of 25.20, a PEG ratio of 2.56 and a beta of 0.47. The stock has a fifty day moving average price of $153.44 and a two-hundred day moving average price of $156.28. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the business posted $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 2.96%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent research reports. Bank of America upped their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday, March 5th. Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Barclays lifted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday. Finally, Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.